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Abstract
Background
Circulating polyunsaturated fatty acid (PUFA) levels are associated with clinical outcomes
in cardiovascular diseases including coronary artery disease and chronic heart failure (HF).
However, their clinical implications in acute decompensated HF (ADHF) remain unclear.
The aim of this study was to investigate the clinical roles of circulating PUFAs in patients
with ADHF.
Methods
Circulating levels of PUFAs, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA),
arachidonic acid (AA) and dihomo-gamma linoleic acid (DGLA), were measured on admis-
sion in 685 consecutive ADHF patients. Adverse events were defined as all-cause death
and worsening HF.
Results
During a median follow-up period of 560 days, 262 (38.2%) patients had adverse events.
Although patients with adverse events had lower n-6 PUFA (AA + DGLA) level than those
without, n-3 PUFA (EPA + DHA) level was comparable between the groups. Kaplan-Meier
analyses showed that lower n-6 PUFA level on admission was significantly associated with
the composite of all-cause death and worsening HF, all-cause death, cardiovascular death
and worsening HF (p < 0.001, p = 0.005, p = 0.021, p = 0.019, respectively). In a multivari-
ate Cox model, lower n-6 PUFA level was independently associated with increased risk of
adverse events (HR 0.996, 95% CI: 0.993–0.999, p = 0.027).
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Conclusions
Lower n-6 but not n-3 PUFA level on admission was significantly related to worse clinical
outcomes in ADHF patients. Measurement of circulating n-6 PUFA levels on admission
might provide information for identifying high risk ADHF patients.
Introduction
Heart failure (HF) is a common and growing public health problem worldwide. Although phar-
macologic and non-pharmacologic therapies have been developed for patients with HF, mortality
and morbidity remain significantly high [1, 2]. It is noteworthy that HF is a multisystem disease
with multiple comorbidities including anemia, renal and hepatic dysfunction,malnutrition and
cardiac cachexia [3–5]. Among them, poor nutritional status has been reported to be strongly
associatedwith worse clinical outcomes in both acute and chronic HF patients [6–8]. Patients
with HF are more prone to malnutrition for a variety of reasons, including symptomatic
anorexia, early satiation, ascites, prescribedmedication, psychological factors and catabolic/ana-
bolic imbalance, which lead to a hypermetabolic state [9–11], and these are frequently observed
in acute decompensatedHF (ADHF) as an advanced stage of HF (stage C or D).
Polyunsaturated fatty acids (PUFAs), which are macronutrients, have usually been shown
to be associated with beneficial health effects on cardiovascular disease (CVD) including coro-
nary artery disease and HF [12, 13]; nevertheless, the two major types of long chain PUFAs,
omega-3 (n-3) and omega-6 (n-6) PUFAs, were shown to have antagonistic effects.While the
n-3 PUFAs emerged as anti-inflammatory and cardioprotective, the n-6 PUFAs were shown to
be proinflammatory [14, 15]. Eicosanoids derived from n-3 PUFAs, such as eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), have been shown to have anti-inflammatory
and antithrombotic effects in experimental and clinical settings, whereas those derived from n-
6 PUFAs, arachidonic acid (AA) and dihomo-gamma linoleic acid (DGLA), act in an opposite
manner. Indeed, despite conflicting evidence [16, 17], several clinical trials have demonstrated
the cardioprotective effects of n-3 PUFAs to reduce cardiovascular events, including sudden
cardiac death and acute myocardial infarction (AMI), in primary and secondary prevention
settings of CVD [18, 19]. Furthermore, in an epidemiological study, decreased n-3 PUFA level
was also associated with worse clinical outcomes following AMI [20]. However, the association
between n-6 PUFAs and CVD and the role of PUFAs in patients with ADHF remain to be
determined.
Because neither n-3 nor n-6 PUFAs can be synthesized de novo in mammals and are consid-
ered nutritionally essential [21], we hypothesize that circulating PUFAs may objectively reflect
dietary consumption and also biologically relevant processes, such as absorption, incorpo-
ration, and metabolism, and therefore impairment of their absorption in decompensatedHF
could relate to worse clinical outcomes.
The aim of the current study was to clarify the roles of PUFAs in the clinical setting of
ADHF.
Methods
Study Design
Data from the National cerebral and cardiovascular center acute DEcompensated heart Failure
(NaDEF) registry, obtained between January 2013 and August 2015, were retrospectively
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analyzed. The NaDEF registry is a single-center, observational, on-going, prospective cohort
that includes all patients requiring hospitalization to our institution for the first time with a
diagnosis of ADHF by at least two experienced cardiologists according to the Framingham
ADHF criteria [22]. Follow-up was performed at 3, 6, 12, and 24 months after discharge by
direct contact with patients or the patients’ physicians in the hospital or outpatient clinic, tele-
phone interviewof patients or, if deceased, family members, and mail, by dedicated coordina-
tors and investigators. Currently, 92.8% of enrolled patients are successfully followed-up. In
this study, because patient information was anonymized and de-identified prior to analyses,
written informed consent was not obtained from each patient. However, we publicized the
study by posting a summary of the protocol (with an easily understood description) on the
website of the National Cerebral and Cardiovascular Center; the notice clearly informed
patients of their right to refuse enrollment. These procedures for informed consent and enroll-
ment are in accordance with the detailed regulations regarding informed consent described in
the guidelines, and this study, including the procedure for enrollment, has been approved by
the Institutional ReviewBoard of the National Cerebral and Cardiovascular Center (M22-025),
and registered under the Japanese UMIN Clinical Trials Registration (UMIN000017024).
Study Population
From the 751 patients enrolled in the NaDEF registry, those with acute coronary syndrome
receiving an EPA or DHA preparation, and those without measurement of PUFAs were
excluded from this study. Finally, 685 patients were examined. Then the patients were divided
into three groups according to the tertiles of n-6 PUFA level (low [< 157 μg/mL], intermediate
[157–198 μg/mL], and high [199 μg/mL] levels) for obtaining more detailed risk stratifica-
tion on future adverse events (Fig 1).
Blood Sampling, PUFA Measurements and Assessment of Nutritional
Status
Venous blood samples were collected on admission, and routine laboratory tests were per-
formed within a day of blood sampling using an automated analyzer, whereas additional mea-
surements including PUFAs were performed afterward using freshly frozen samples kept at –
80°C. Frozen serum samples were shipped to LSI Medience Corp., Tokyo, Japan, and EPA,
DHA, AA and DGLAwere measured by LC-MS/MSmethod, using a LC-MS8030 system (Shi-
madzu Corp., Kyoto, Japan). For the assessment of nutritional status, we used geriatric nutri-
tional risk index (GNRI) which derived based on serum albumin level and body weight and
has been recently validated for risk stratification in Japanese elderly ADHF patients [23].
Study Endpoints
The study endpoints were all-cause death, cardiovascular death and worsening HF, which was
defined as worsening of symptoms and signs of HF requiring intensification of intravenous
therapy or initiation of mechanical support during hospitalization, as used in major ADHF
clinical trials [24, 25], or readmission because of HF after discharge.
Statistical Analyses
Results are presented as mean ± SD when normally distributed, and as median and interquar-
tile range (IQR) when non-normally distributed. Differences between groups were analyzed by
unpaired Student’s t-test, Mann-Whitney U test, or ANOVA for continuous variables, and by
chi-squared test or Fisher’s exact test for dichotomous variables, when appropriate. For survival
PUFAs in Acute Heart Failure
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Fig 1. Flow diagram of study population.
doi:10.1371/journal.pone.0165841.g001
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analyses, Kaplan-Meier survival plots were constructed by dividing n-6 PUFA levels on admis-
sion into tertiles (low, intermediate, and high levels), and log-rank testing was performed, to
study the influence of n-6 PUFA levels on all-cause death, cardiovascular death and worsening
HF. To evaluate the influence of n-6 PUFA levels on all-cause death and worsening HF, we
constructed the following three Cox proportional-hazards regression models: model 1, crude;
model 2, age, sex-adjusted; and model 3, fully adjusted. In model 3, based on the variables
achieving p< 0.10 on univariate Cox analysis for adverse events and/or significant association
with n-6 PUFA level, we included the following covariates: age, sex, ischemic cardiomyopathy
etiology, systolic blood pressure, heart rate, estimated glomerular filtration rate (eGFR), GNRI,
and hemoglobin, serum sodium, brain natriuretic peptide, total cholesterol, total bilirubin and
C-reactive protein (CRP) levels, and history of atrial fibrillation, dyslipidemia, diabetes and
chronic kidney disease, and use of statins, diuretics, spironolactone, angiotensin-converting
enzyme inhibitors (ACE-Is) or angiotensin II receptor blockers (ARBs), beta blockers and
intravenous inotropes. All tests were two tailed, and a value of p< 0.05 was considered statisti-
cally significant. All analyses were performedwith SPSS1 for Windows version 23.0 (IBM,
Corp., Armonk, NY, USA) and STATA 1 13 (Stata Corp., College Station, TX, USA).
Results
Baseline Characteristics and PUFA Levels in Patients With and Without
Adverse Events
Of the 683 study patients, 262 (38.2%) had adverse events (all-cause death or worseningHF) dur-
ing a median follow-up period of 560 days (interquartile range: 340 to 800 days). Mean age was
76 years, 60% were men, and median left ventricular ejection fraction (LVEF) was 37%. Regard-
ing the etiologyof HF, ischemic cardiomyopathy comprised 24%. Patients with adverse events
had higher age, higher prevalence of diabetes, chronic kidney disease, atrial fibrillation, ischemic
cardiomyopathy etiology, ACE-Is or ARBs use, beta blockers use, diuretic use, statin use and
intravenous inotropic use, higher brain natriuretic peptide, total bilirubin and CRP levels, and
lower GNRI, heart rate, systolic blood pressure and eGFR, and lower hemoglobin, sodium, total
cholesterol and albumin levels compared to those without adverse events (Tables 1 and 2).
The distribution of PUFA levels is shown in Fig 2; median PUFA (EPA, DHA, AA and
DGLA) levels on admission were 40, 108, 153 and 25 μg/mL, respectively. Table 2 compares
the levels and ratios of PUFAs in patients with and without adverse events. Although patients
with adverse events had lower DHA, AA, DGLA, and n-6 (AA + DGLA) levels than those with-
out, EPA and n-3 (EPA + DHA) levels, and EPA/AA, DHA/AA and n-3/n-6 ratios were com-
parable between the groups. In the present prospective cohort, n-6 rather than n-3 PUFA levels
were associated with adverse events.
Baseline Characteristics by Tertiles of N-6 PUFA Level
Baseline clinical characteristics are shown in Tables 3 and 4. Although patients with low n-6
PUFA level were older and had lower GNRI, systolic blood pressure, hemoglobin, eGFR, sodium,
total cholesterol, albumin, EPA and DHA levels, and lower prevalence of statin use compared to
those with high n-6 PUFA, there were no significant differences in New York Heart Association
functional class, LVEF, etiologyof HF and prevalence of hemodialysis among the tertiles.
N-6 PUFA Level and Clinical Outcomes
Kaplan-Meier analyses showed that lower total n-6 PUFA level on admission was significantly
associated with worse clinical outcomes including the composite of all-cause death and
PUFAs in Acute Heart Failure
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worsening HF, all-cause death, cardiovascular death and worsening HF (log-rank; p< 0.001,
p = 0.005, p = 0.021, p = 0.019, respectively, Fig 3). Cox proportional hazard analyses revealed
that per point increase in n-6 PUFA level was associated with increased risk of adverse events
[hazard ratio (HR): 0.994, 95% confidence interval (CI): 0.992–0.997, p< 0.001; HR: 0.995,
95% CI: 0.993–0.997, p< 0.001; and HR: 0.996, 95% CI: 0.993–0.999, p = 0.027; for models 1,
2, and 3, respectively], and patients with low n-6 PUFA level had a 1.4-fold increase in the risk
of adverse events as compared with those with high n-6 PUFA level (p = 0.037, Table 5).
Discussion
The present study has shown that patients with lower n-6 PUFA level have a significantly
higher incidence of adverse events (all-cause death and worsening HF) following ADHF,
whereas n-3 PUFA level showed no significant association. Patients with lower n-6 PUFA level
Table 1. Baseline characteristics in patients with and without adverse events.
Variable Overall (N = 685) Events (N = 262) No events (N = 423) P-value
Age, years 76 ± 12 77 ± 11 75 ± 12 0.006
Male, n (%) 410 (60) 165 (63) 245 (58) 0.20
Body mass index 23.0 ± 4.3 22.5 ± 3.6 23.3 ± 4.6 0.016
GNRI 99.6 ± 11.2 97.1 ± 10.2 101.1 ± 11.5 <0.001
Past history, n (%)
Hypertension 506 (74) 195 (74) 311 (74) 0.86
Diabetes 251 (37) 116 (44) 135 (32) 0.001
Dyslipidemia 361 (53) 143 (55) 218 (52) 0.48
CKD 363 (53) 183 (70) 180 (43) <0.001
Hemodialysis 13 (2) 7 (3) 6 (1) 0.26
Prior MI 159 (23) 73 (28) 86 (20) 0.025
Atrial fibrillation 354 (52) 156 (60) 198 (47) 0.001
NYHA III or IV, n (%) 552 (81) 209 (80) 343 (81) 0.69
Heart rate, beat/min 92 ± 28 89 ± 25 94 ± 30 0.023
Systolic BP, mmHg 140 ± 32 133 ± 32 144 ± 31 <0.001
LVEF, % 37 (23,54) 35 (20,50) 39 (25,55) 0.15
Etiology, n (%)
ICM 166 (24) 75 (29) 91 (22) <0.001
DCM 119 (17) 37 (14) 82 (19)
HCM 28 (4) 19 (7) 9 (2)
HHD 70 (10) 19 (7) 51 (12)
Valves 166 (24) 65 (25) 101 (24)
Oral medication on admission, n (%)
ACE-Is or ARBs 361 (53) 154 (59) 207 (49) 0.015
Beta blockers 358 (52) 162 (62) 196 (46) <0.001
Diuretics 378 (55) 179 (68) 199 (47) <0.001
Spironolactone 140 (20) 69 (26) 71 (17) 0.003
Statins 249 (36) 108 (41) 141 (33) 0.041
Continuous variables are presented as mean ± SD if normally distributed, and median (interquartile range) if not normally distributed. Categorical variables
are presented as number of patients (%). ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BP = blood pressure;
CKD = chronic kidney disease; DCM = dilated cardiomyopathy; GNRI = geriatric nutritional risk index; HCM = hypertrophic cardiomyopathy;
HHD = hypertensive heart disease; ICM = ischemic cardiomyopathy; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York
Heart Association.
doi:10.1371/journal.pone.0165841.t001
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also had multiple co-morbid conditions including anemia and renal insufficiency. Further-
more, multivariate Cox analyses showed a lower n-6 PUFA level to be an independent determi-
nant of adverse events. These findings suggest that n-6 rather than n-3 PUFA levels might be
useful for identifying patients at high risk of adverse events following ADHF.
Although we could not explore the direct mechanisms for the association between lower n-6
PUFAs and worse clinical outcomes, there are several possible explanations. First, “consump-
tion as a source of pro-inflammatory eicosanoids”; it has been strongly suggested that the two
major types of long chain PUFAs, n-3 and n-6 PUFAs, have antagonistic effects.While the n-3
PUFAs emerged as cardioprotective, the n-6 PUFAs were shown to be pro-inflammatory [14,
15]. However, relevant intervention trials failed to link n-6 with a pro-inflammatory response
[26–28]. Among them, Poudel-Tandukar et al. investigated the relationship between essential
fatty acid status and CRP, and n-6 PUFAs were found to be inversely associated with serum
CRP [28]. In the present study, n-6 PUFA levels also tended to be inversely associated with
serumCRP level. N-6 PUFAs are known to be a major source of pro-inflammatory eicosa-
noids, and therefore it is speculated that n-6 PUFAs might be consumed by enhanced inflam-
matory responses in high risk ADHF patients. Second, “decreased production of vasodilators”;
Table 2. Findings of laboratory tests and intravenous treatment in patients with and without adverse events.
Variable Overall (N = 685) Events (N = 262) No events (N = 423) P-value
Laboratory data on admission
Hemoglobin, g/dL 12.0 ± 2.1 11.5 ± 2.1 12.2 ± 2.1 <0.001
Sodium, mEq/L 140 (138,142) 139 (137,142) 141 (138,143) <0.001
eGFR, ml/min 37.2 (25.1,49.0) 30.6 (20.2,40.5) 41.2 (28.8,53.5) <0.001
BNP, pg/dL 605 (323,1114) 732 (393,1388) 551 (276,983) 0.001
hs TnT, ng/mL 0.04 (0.02,0.07) 0.05 (0.03,0.09) 0.03 (0.02,0.06) 0.73
Total bilirubin, mg/dL 0.3 (0.2,0.4) 0.3 (0.2, 0.5) 0.3 (0.2,0.4) <0.001
Total cholesterol, mg/dL 157 ± 40 152 ± 41 161 ± 40 0.005
Albumin, g/dL 3.8 ± 0.4 3.7 ± 0.5 3.8 ± 0.4 <0.001
CRP, mg/dL 0.4 (0.1,1.2) 0.5 (0.2,2.1) 0.3 (0.1,0.9) 0.003
Fatty acids concentration
EPA, μg/mL 40 (26,62) 39 (24,64) 40 (26,62) 0.71
DHA, μg/mL 108 (83,138) 101 (77,138) 111 (86,139) 0.018
AA, μg/mL 153 (123,182) 144 (113,169) 157 (129,188) <0.001
DGLA, μg/mL 25 (18,33) 22 (17,30) 26 (20,35) <0.001
N-3 PUFAs, μg/mL 151 (113,202) 146 (108,202) 154 (116,202) 0.11
N-6 PUFAs, μg/mL 178 (144,210) 166 (133,199) 187 (152,218) <0.001
Fatty acids ratio
EPA/AA 0.27 (0.18,0.40) 0.28 (0.18,0.45) 0.26 (0.17,0.37) 0.26
DHA/AA 0.72 (0.57,0.91) 0.73 (0.59,0.95) 0.71 (0.57,0.88) 0.11
N-3/N-6 PUFAs 0.86 (0.65,1.11) 0.88 (0.67,1.16) 0.84 (0.64,1.08) 0.14
Intravenous treatment, n (%)
Diuretics 509 (75) 191 (74) 318 (76) 0.65
Vasodilators 412 (61) 149 (57) 263 (63) 0.13
Inotropes 94 (14) 54 (21) 40 (10) <0.001
Continuous variables are presented as mean ± SD if normally distributed, and median (interquartile range) if not normally distributed. Categorical variables
are presented as number of patients (%). AA = arachidonic acid; BNP = brain natriuretic peptide; CRP = C-reactive protein; DGLA = dihomo-gamma-
linolenic acid; DHA = docosahexaenoic acid; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; hs TnT = high sensitive troponin T;
N-3 = omega-3; N-6 = omega-6; PUFAs = polyunsaturated fatty acids.
doi:10.1371/journal.pone.0165841.t002
PUFAs in Acute Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0165841 November 8, 2016 7 / 16
PUFAs in Acute Heart Failure
PLOS ONE | DOI:10.1371/journal.pone.0165841 November 8, 2016 8 / 16
DGLA and AA are known to become several sources of respective different vasoactive eicosa-
noids. DGLA and AA are sources of prostaglandins (PG) of 1 series, and PG of 2 series, throm-
boxanes, leukotrienes of 4 series and nitric oxide (NO), respectively [29]. Among them, PGE1,
which is formed from DGLA and is a potent arteriolar vasodilator, has beneficial effects on
myocardial energetics and cardiac function in patients with severe ischemic HF [30]. PGI2
(prostacyclin), a product of AA, could have similar beneficial actions in view of the fact that
PGI2 is also a potent vasodilator and possesses antiarrhythmic actions, similarly to PGE1 [31–
34]. These PGs are known to enhance NO synthesis and release [35–38], suggesting that NO
Fig 2. Distribution of PUFA levels. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AA,
arachidonic acid; DGLA, dihomo-gamma linoleic acid.
doi:10.1371/journal.pone.0165841.g002
Table 3. Baseline characteristics by tertiles of n-6 PUFA level.
Variable Overall (N = 685) Low (N = 228) Intermediate (N = 226) High (N = 231) P-value
N-6 range, μg/mL - < 157 157–198 199 -
Age, years 76 ± 12 77 ± 11 76 ± 11 73 ± 13 0.008
Male, n (%) 410 (60) 151 (66) 134 (59) 125 (54) 0.029
Body mass index 23.0 ± 4.3 22.9 ± 4.2 22.9 ± 4.2 23.2 ± 4.4 0.67
GNRI 99.6 ± 11.2 97.5 ± 11.2 99.6 ± 10.4 101.6 ± 11.6 <0.001
Past history, n (%)
Hypertension 506 (74) 161 (71) 166 (73) 179 (77) 0.24
Diabetes 251 (37) 92 (40) 69 (31) 90 (39) 0.059
Dyslipidemia 361 (53) 104 (46) 107 (47) 150 (65) < 0.001
CKD 363 (53) 143 (63) 108 (48) 112 (49) 0.002
Hemodialysis 13 (2) 5 (2) 6 (3) 2 (1) 0.35
Prior MI 159 (23) 54 (24) 51 (23) 54 (23) 0.95
Atrial fibrillation 354 (52) 142 (62) 110 (49) 102 (44) <0.001
NYHA III or IV, n (%) 552 (81) 190 (83) 180 (80) 182 (79) 0.42
Heart rate, beat/min 92 ± 28 86 ± 26 95 ± 28 95 ± 31 0.001
Systolic BP, mmHg 140 ± 32 133 ± 32 140 ± 30 146 ± 32 <0.001
LVEF, % 37 (23,54) 38 (23,55) 37 (23,52) 35 (22,54) 0.94
Etiology, n (%)
ICM 166 (24) 57 (25) 52 (23) 57 (25) 0.73
DCM 119 (17) 34 (15) 43 (19) 42 (18)
HCM 28 (4) 13 (6) 9 (4) 6 (3)
HHD 70 (10) 21 (9) 20 (9) 29 (13)
Valves 166 (24) 55 (24) 59 (26) 52 (23)
Oral medication on admission, n (%)
ACE-Is or ARBs 361 (53) 129 (57) 111 (49) 121 (53) 0.26
Beta blockers 358 (52) 128 (56) 114 (50) 116 (50) 0.37
Diuretics 378 (55) 152 (67) 120 (53) 106 (46) <0.001
Spironolactone 140 (20) 54 (24) 43 (19) 43 (19) 0.34
Statins 249 (36) 67 (29) 76 (34) 106 (46) < 0.001
Continuous variables are presented as mean ± SD if normally distributed, and median (interquartile range) if not normally distributed. Categorical variables
are presented as number of patients (%). ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BP = blood pressure;
CKD = chronic kidney disease; DCM = dilated cardiomyopathy; GNRI = geriatric nutritional risk index; HCM = hypertrophic cardiomyopathy;
HHD = hypertensive heart disease; ICM = ischemic cardiomyopathy; LVEF = left ventricular ejection fraction; MI = myocardial infarction; N-6 = omega-6;
NYHA = New York Heart Association.
doi:10.1371/journal.pone.0165841.t003
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and PGs act in concert with each other to modulate cardiac function. They are also potent
inhibitors of atherosclerosis, and interference with their action, as by free radicals, could lead to
HF [39]. Taking these findings together, it is proposed that deficiency of n-6 PUFAs, especially
DGLA and AA, may cause decreased production of PGE1, PGI2 and NO, thereby resulting in a
decompensated state of HF. Third, “insufficiencydue to malnutrition”; HF may promote mal-
nutrition based on several mechanisms including gut edema, anorexia from inflammatory
cytokine production, limitation in eating and food preparation due to fatigue, and increased
work of breathing, especially in advanced right sided HF [40]. Despite the underlyingmecha-
nisms being unclear, insufficiencyof n-6 PUFAs may occurmore readily compared with that
of n-3 PUFAs in advanced HF patients.
The effects of PUFAs as dietetic management in HF patients are controversial; therefore, lit-
tle information is provided in the major HF management guidelines [41–43]. In spite of the
fact that the Gruppo Italiano per lo Studio della Sopravvivenza nell'InfartoMiocardico-Heart
Failure (GISSI-HF) trial showed a modest survival advantage from n-3 PUFA supplementation
in HF [44], several recent clinical trials failed to show clear benefit from n-3 PUFAs in high
risk patients with cardiovascular disease [17, 45]. In contrast, in animal models of congestive
HF, higher dietary n-6 PUFA protected against the development of cardiac hypertrophy and
systolic dysfunction, and improved total mortality [46, 47]; however, in patients with coronary
artery disease, previous reports examining the effect of n-6 PUFA intake showed inconsistent
Table 4. Findings of laboratory tests and intravenous treatment by tertiles of n-6 PUFA level.
Variable Overall (N = 685) Low (N = 228) Intermediate (N = 226) High (N = 231) P-value
N-6 range, μg/mL - < 157 157–198 199 -
Laboratory data on admission
Hemoglobin, g/dL 12.0 ± 2.1 11.4 ± 2.2 11.9 ± 1.9 12.6 ± 2.1 <0.001
Sodium, mEq/L 140 (138,142) 139 (137,142) 140 (138,143) 140 (138,143) <0.001
eGFR, ml/min 37.2 (25.1,49.0) 32.7 (21.9,44.8) 37.8 (27.6,51.5) 40.2 (27.3,51.3) <0.001
BNP, pg/dL 605 (323,1114) 574 (323,1377) 663 (319,1154) 610 (337,944) 0.057
hs TnT, ng/mL 0.04 (0.02,0.07) 0.04 (0.03,0.07) 0.04 (0.02,0.07) 0.04 (0.02,0.06) 0.33
Total bilirubin, mg/dL 0.3 (0.2,0.4) 0.3 (0.2,0.6) 0.3 (0.2,0.4) 0.2 (0.2,0.3) <0.001
Total cholesterol, mg/dL 157 ± 40 132 ± 29 159 ± 32 180 ± 43 <0.001
Albumin, g/dL 3.8 ± 0.4 3.6 ± 0.5 3.8 ± 0.4 3.9 ± 0.4 <0.001
CRP, mg/dL 0.4 (0.1,1.2) 0.5 (0.2,1.6) 0.5 (0.2,1.5) 0.3 (0.1,0.8) 0.11
AA, μg/mL 153 (123,182) 111 (95,123) 153 (144,160) 197 (181,231) <0.001
DGLA, μg/mL 25 (18,33) 17 (15,22) 26 (20,31) 35 (27,42) <0.001
EPA, μg/mL 40 (26,62) 29 (21,48) 43 (29,69) 48 (33,68) <0.001
DHA, μg/mL 108 (83,138) 87 (67,109) 114 (89,139) 129 (98,158) <0.001
Systolic BP, mmHg 140 ± 32 133 ± 32 140 ± 30 146 ± 32 <0.001
LVEF, % 37 (23,54) 38 (23,55) 37 (23,52) 35 (22,54) 0.94
Intravenous treatment, n (%)
Diuretics 509 (75) 164 (72) 176 (79) 169 (73) 0.22
Vasodilators 412 (61) 120 (53) 134 (60) 158 (69) 0.002
Inotropes 94 (14) 34 (15) 31 (14) 29 (13) 0.73
Continuous variables are presented as mean ± SD if normally distributed, and median (interquartile range) if not normally distributed. Categorical variables
are presented as number of patients (%). AA = arachidonic acid; BNP = brain natriuretic peptide; CRP = C-reactive protein; DGLA = dihomo-gamma-
linolenic acid; DHA = docosahexaenoic acid; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; hs TnT = high sensitive troponin T;
N-6 = omega-6.
doi:10.1371/journal.pone.0165841.t004
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results [48–50]. Adequately powered and well-designed randomized control trials to show the
benefit of n-6 PUFAs are needed.
Study Limitations
First, no information was available with regard to lifestyle and dietary intake of PUFAs; there-
fore, we could not exclude the influence of dietary intake on PUFA levels. Second, PUFAs were
not measured in the cell membrane. PUFAs in the cell membrane were reported to be direct
precursors of pro- and anti-inflammatory eicosanoids. However, it was reported that cell mem-
brane EPA/AA ratio was strongly correlated with serumEPA/AA ratio in the Japanese popula-
tion [51]. Third, we measured only EPA and DHA as n-3 PUFAs, and AA and DGLA as n-6
PUFAs among all PUFAs, although these four metabolites are representative precursors of
eicosanoids that may affect the cardiovascular system. Finally, low n-6 PUFAs group were
older and worse in their renal function;moreover, total bilirubin and cholesterol, albumin, and
all fatty acids levels as well as GNRI were lower in the low n-6 PUFAs group. Therefore, low n-
6 PUFAs level might reflect older chronic kidney disease with malnutrition.
Conclusions
Lower n-6 PUFA level on admission was significantly related to worse clinical outcomes in
ADHF patients, whereas n-3 PUFA level was not. These results suggest that measurement of
circulating n-6 PUFAs rather than n-3 PUFAs levels on admission might provide information
for risk stratification of ADHF patients.
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